Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
Conditions
- Autosomal Dominant Polycystic Kidney Disease
Interventions
- DRUG: Placebo
- DRUG: Everolimus
Sponsor
Novartis Pharmaceuticals